Frank A Wollheim

Summary

Affiliation: Lund University Hospital
Country: Sweden

Publications

  1. ncbi Aspects of science in Scandinavian rheumatology--the making of a specialty
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 34:4-13. 2005
  2. ncbi To keep the catch - that is the question: a personal account of the 3rd Annual EULAR Congress, Stockholm
    Frank A Wollheim
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Arthritis Res 4:E007. 2002
  3. ncbi Drug resistance in rheumatology: an area in search of investigators
    Frank A Wollheim
    Department of Rheumatology, Lund University Hospital, S-221 85 Lund, Sweden
    Curr Rheumatol Rep 5:333-5. 2003
  4. ncbi Early stages of osteoarthritis: the search for sensitive predictors
    F A Wollheim
    Department of Rheumatology, University of Lund Hospital, Sweden
    Ann Rheum Dis 62:1031-2. 2003
  5. ncbi [New studies of COX-inhibitors, yet issues remain]
    Frank A Wollheim
    Reumatologiska kliniken, Universitetssjukhuset i Lund
    Lakartidningen 100:2927-31. 2003
  6. ncbi [Per aspera ad astra? Re-establish the responsibility of university clinics for clinical research!]
    Frank A Wollheim
    Lakartidningen 100:2618-9. 2003
  7. ncbi [The CLASS study and its scientific statement. Ethical publishing rules neglected]
    Frank A Wollheim
    Reumatologiska kliniken, Universitetssjukhuset i Lund
    Lakartidningen 99:3934-5. 2002
  8. ncbi Classification of systemic sclerosis. Visions and reality
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, S 21774 Lund, Sweden
    Rheumatology (Oxford) 44:1212-6. 2005
  9. ncbi Enteropathic arthritis: how do the joints talk with the gut?
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, University of Lund, Lund, Sweden
    Curr Opin Rheumatol 13:305-9. 2001
  10. ncbi Approaches to rheumatoid arthritis in 2000
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, University of Lund, Lund, Sweden
    Curr Opin Rheumatol 13:193-201. 2001

Collaborators

Detail Information

Publications27

  1. ncbi Aspects of science in Scandinavian rheumatology--the making of a specialty
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Scand J Rheumatol 34:4-13. 2005
    ..Inter-Scandinavian links as manifested in congresses and in the Journal are the visible superstructure of a far deeper and fertile common culture...
  2. ncbi To keep the catch - that is the question: a personal account of the 3rd Annual EULAR Congress, Stockholm
    Frank A Wollheim
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Arthritis Res 4:E007. 2002
    ..The Annual EULAR Congress consolidates its position as one of the two most important annual congresses of rheumatology, but EULAR economy and commercial aspects are still too dominant in relation to science...
  3. ncbi Drug resistance in rheumatology: an area in search of investigators
    Frank A Wollheim
    Department of Rheumatology, Lund University Hospital, S-221 85 Lund, Sweden
    Curr Rheumatol Rep 5:333-5. 2003
  4. ncbi Early stages of osteoarthritis: the search for sensitive predictors
    F A Wollheim
    Department of Rheumatology, University of Lund Hospital, Sweden
    Ann Rheum Dis 62:1031-2. 2003
  5. ncbi [New studies of COX-inhibitors, yet issues remain]
    Frank A Wollheim
    Reumatologiska kliniken, Universitetssjukhuset i Lund
    Lakartidningen 100:2927-31. 2003
    ..The Swedish Council on Technology Assessment in Health Care, in its "SBU Alert", has published an appraisal of celecoxib and rofecoxib, in which the need for further long-term safety studies is emphasized...
  6. ncbi [Per aspera ad astra? Re-establish the responsibility of university clinics for clinical research!]
    Frank A Wollheim
    Lakartidningen 100:2618-9. 2003
  7. ncbi [The CLASS study and its scientific statement. Ethical publishing rules neglected]
    Frank A Wollheim
    Reumatologiska kliniken, Universitetssjukhuset i Lund
    Lakartidningen 99:3934-5. 2002
  8. ncbi Classification of systemic sclerosis. Visions and reality
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, S 21774 Lund, Sweden
    Rheumatology (Oxford) 44:1212-6. 2005
    ..There is no convincing evidence of any advantage for distinguishing the limited, intermediate and diffuse forms of SSc rather than only the limited and diffuse forms...
  9. ncbi Enteropathic arthritis: how do the joints talk with the gut?
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, University of Lund, Lund, Sweden
    Curr Opin Rheumatol 13:305-9. 2001
    ..A new mechanism implicating dimeric HLA-B27 heavy chains in the pathogenesis of enteropathic arthritis is also presented. Despite evidence for persisting antigen presence, antimicrobial therapy seems ineffective in reactive arthritis...
  10. ncbi Approaches to rheumatoid arthritis in 2000
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, University of Lund, Lund, Sweden
    Curr Opin Rheumatol 13:193-201. 2001
    ..One major worry relates to chronic inflammation in RA and other rheumatic diseases as putative cause of accelerated atherosclerosis...
  11. ncbi Serum markers of articular cartilage damage and repair
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, Sweden
    Rheum Dis Clin North Am 25:417-32, viii. 1999
    ..Analyses of serum are less specific and less sensitive than analyses of synovial fluid, but their use as research tools in clinical studies, drug development, and experimental work in animal models is increasing...
  12. ncbi Markers of disease in rheumatoid arthritis
    F A Wollheim
    Department of Rheumatology, Lund University Hospital, Sweden
    Curr Opin Rheumatol 12:200-4. 2000
    ..They will, however, give important insight into pathogenic processes, and may help in evaluating new therapy. Finally, markers originally identified in humans have now proven their value in experimental arthritis...
  13. ncbi [Interleukin-18 and new drugs. Protective effect against tumor growth and infections]
    F A Wollheim
    Reumatologiska kliniken, Universitetssjukhuset i Lund
    Lakartidningen 97:4604. 2000
    ..It focuses on the role of IL-18 modulation in tumours, infections and autoimmune and inflammatory diseases...
  14. ncbi Prescription of glucosamine for osteoarthritis: does it work and is it safe?
    Frank A Wollheim
    Department of Rheumatology, Lund University Hospital, Lund, Sweden
    Nat Clin Pract Rheumatol 3:364-5. 2007
  15. ncbi Serum IL-15 in patients with early systemic sclerosis: a potential novel marker of lung disease
    Dirk M Wuttge
    Department of Rheumatology, Lund University Hospital, S 221 85 Lund, Sweden
    Arthritis Res Ther 9:R85. 2007
    ..IL-15 may contribute to the pathogenesis of SSc. IL-15 could also be a candidate biomarker for pulmonary involvement and a target for therapy in SSc...
  16. ncbi TNF inhibition as therapy for rheumatoid arthritis
    Frank A Wollheim
    Department of Rheumatology, Lund University Hospital, SE221 85 Lund, Sweden
    Expert Opin Investig Drugs 11:947-53. 2002
    ..Both abnormalities are seemingly ameliorated by TNF inhibition. Anti-apoptotic strategies will soon go into development for control of unresponsive rheumatoid arthritis...
  17. ncbi Aging, muscles, and rheumatoid arthritis
    Frank A Wollheim
    Department of Rheumatology, Lund University Hospital, S-221 85 Lund, Sweden
    Curr Rheumatol Rep 8:323-4. 2006
  18. ncbi Von Willebrand factor propeptide as a marker of disease activity in systemic sclerosis (scleroderma)
    A Scheja
    Department of Rheumatology, University Hospital, Lund, Sweden
    Arthritis Res 3:178-82. 2001
    ..Our results suggest that the propeptide, despite a shorter circulating half-time and lower plasma concentrations than vWf, is more useful in the assessment of disease activity in SSc...
  19. ncbi Long-term evaluation of penicillamine or cyclofenil in systemic sclerosis. Results from a two-year randomized study
    A Akesson
    Department of Rheumatology, University Hospital, Lund, Sweden
    Scand J Rheumatol 21:238-44. 1992
    ..This study thus shows little overall effect of penicillamine and cyclofenil, although both drugs may arrest worsening of pulmonary dysfunction...
  20. ncbi Disease severity of 100 patients with systemic sclerosis over a period of 14 years: using a modified Medsger scale
    A J Geirsson
    Department of Rheumatology, University Hospital, Lund, Sweden
    Ann Rheum Dis 60:1117-22. 2001
    ..To assess organ involvement according to a modified Medsger severity scale and its relation to outcome and prognosis in patients with systemic sclerosis...
  21. ncbi [Meager support for herbal therapy of rheumatoid arthritis]
    F A Wollheim
    Reumatologiska kliniken, Universitetssjukhuset i Lund
    Lakartidningen 98:4434-6. 2001
    ..Although it was stated in the review that safety was probably good, this is not apparent from the presented material...
  22. ncbi The effect of therapeutic glucocorticoids on the adrenal response in a randomized controlled trial in patients with rheumatoid arthritis
    John R Kirwan
    University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, UK
    Arthritis Rheum 54:1415-21. 2006
    ..To measure the effect of low-dose systemic glucocorticoid treatment on the adrenal response to adrenocorticotropic hormone (ACTH) in patients with rheumatoid arthritis (RA)...
  23. ncbi Genetics and susceptibility to RA--more than HLA
    Frank A Wollheim
    Scand J Rheumatol 32:196. 2003
  24. ncbi Treatment of pulmonary fibrosis in systemic sclerosis: light at the end of the tunnel?
    Frank A Wollheim
    Arthritis Rheum 56:9-12. 2007
  25. ncbi Outcome measurements in scleroderma: results from a delphi exercise
    Hashim Gazi
    Division of Rheumatology, Department of Medicine, The University of Western Ontario, London, Ontario, Canada
    J Rheumatol 34:501-9. 2007
    ..To obtain a consensus on the minimal clinically relevant treatment effect in various scleroderma disease outcome measures to be used in future clinical trials...
  26. ncbi Management of intestinal involvement in systemic sclerosis
    Frank A Wollheim
    J Clin Rheumatol 13:116-8. 2007
  27. ncbi Development of a provisional core set of response measures for clinical trials of systemic sclerosis
    D Khanna
    Division of Rheumatology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, California 90095, USA
    Ann Rheum Dis 67:703-9. 2008
    ..To develop a provisional core set of response measures for clinical trials of systemic sclerosis (SSc)...